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Abstract
Introduction: In the modern world, the problem of alimentary obesity is becoming one of the global problems affecting 
all countries. Desynchronosis of bodily rhythms is another possible cause of development of alimentary obesity and 
metabolic syndrome. Thus, the purpose of this research was to study the influence of melatonin on the dynamics of 
body weight in rats.
Materials and Methods: The experiment was carried out on 150 white non-pedigree rats (females and males), which 
were divided into 3 groups (intact, control, experimental) and 3 series (immature, mature and senile rats). The animals 
of the control group received refined palm oil at a dose of 30 g/kg for a period of 6 weeks in their daily diet. The rats of 
the experimental group received melatonin at a dose of 1.9 mg/kg per day intragastrically for 35 days, after the 6-week 
period of excess palm oil intake was over. During the experiment, once every 7 days, the animals’ weight check was 
done, followed by assessing the dynamics of weight gain in rats in different age groups.
Results and Discussion: It was determined that, in the group of the immature animals, an intake of palm oil resulted in 
the most obvious significant changes in the body weight over time. An increase in the total cholesterol and triglycerides 
concentration was observed in the biochemical blood tests of the animals of various age groups.
Conclusion: The use of melatonin at a dose of 1.9 mg/kg per day for 35 days proved highly effective in the animals 
of all age groups and led to a significant alignment of changes in the biochemical parameters studied in the rats of all 
ontogenesis periods.
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Introduction
At present, obesity is one of the most common chronic 
diseases in the world. Being an important biomedical pro­
blem, obesity makes a greater contribution to morbidity 
than infectious diseases (Perederiy et al. 2013, Burkov
and Ivleva Aya 2010, Solovyov et al. 2011). Overall, this 
problem is becoming one of those globally affecting all 
countries. According to the WHO data, there are over 1.7 
billion people in the world who are overweight or obe­
se. In most European countries, between 15% and 25% 
of the adult population suffer from obesity (Anonymous
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2010, Bacquer et al. 2009). This pathology is most wi­
despread in the United States, where the proportion of 
people suffering from obesity is 35% of the total popula­
tion. It should also be emphasised that, according to the 
WHO data, in most countries of Europe from 25% to 70% 
of the population are overweight. In Russia, more than 
60% of the population are overweight and about 26% suf­
fer from obesity. The consequence is a 9-year decrease 
in life expectancy for women and a 12-year decrease for 
men (Vitebskaya 2010, Rapoport et al. 2013).
Moreover, the obesity rate in children and teenagers 
is observed to have been increasing worldwide of late: 
in well-developed countries, 25% of teenagers are over­
weight and 15% suffer from obesity. Being overweight 
in childhood is an important predictor of obesity in adul­
thood: 50% of children who were overweight at age 6 
become obese in adulthood and, in adolescence, this pro­
bability increases to 80% (Averyanov 2009, Zagoruiko et 
al. 2010, Kartelishev and Smirnova 2013).
If the current trends continue, by 2030, the expected 
number of overweight people will have reached 3.3 billi­
on people (Kravchuk and Galagudza 2014, Nduhiradandi 
et al. 2012).
In terms of gender, statistics are as follows: 10% of 
adult men and 14% of adult women in the world suffer 
from obesity, the total number reaching over 500 million 
people (Samorodskaya et al. 2015, Peschke and Mulh- 
bauer 2010).
Obesity is heterogeneous from the genetic, physiolo­
gical and psychological points of view. It is considered 
to be a psychosomatic disease (Luzina et al. 2013). De­
pression and anxiety often precede the development of 
obesity and the degree of severity of mental symptoms 
correlates with anthropometric and biochemical disorders 
attributable to obesity (Romantsova 2011).
Over the last two centuries, widespread mechanisation 
and automation in everyday life and at work have resulted 
in hypodynamia in a significant portion of the population. 
An unhealthy lifestyle along with excessive consumption 
of food which is rich in fats and carbohydrates results in 
an imbalance in energy expenditure, certain changes in a 
number of biochemical processes and an increase in body 
weight (Strueva et al. 2013).
It has been recently found that another reason for the 
development of alimentary obesity and metabolic syndro­
me is desynchronosis of biological rhythms, which shows 
in disorders of internal organs due to the imbalance of 
the suprachiasmatic nucleus of the hypothalamus and 
depression of the secretory activity of the epiphysis (Ar- 
ushanyan 2012a, Baksheev and Kolomoets 2011, Ryaza­
nova 2014, Kitagawa et al. 2012). In the modern world, 
a person very often stays indoors with artificial lighting 
during night hours. These include: numerous nightspots, 
general illumination of buildings, streets, as well as the 
habit of staying in front of TV sets and various gadgets 
for an extended period.
The dysregulation of the sleep-wake cycle can be an 
etiological cause of insulin resistance and concomitant
systemic hyperinsulinemia (Ryazanova 2014, Dzherieva et 
al. 2012, Kotova 2011, Mikhailova and Shalenkova 2014).
A Belgian study by D. De Bacguer et al., 2012 demon­
strated deterioration of the lipid profile accompanied by 
a decrease in the level of high-density lipoprotein (HDL) 
and an increase in the level of triglycerides (TG), as well 
as an increase in blood pressure (BP) and body weight, for 
people working in night-shifts compared to those working 
only during the daytime (Tereshchuk et al. 2014, Srinivasa 
et al. 2013). American scientists have determined the rela­
tionship between the time that the subject spends in front of 
the illuminated TV and computer screen and the develop­
ment of abdominal obesity, dyslipidemia and hypertension 
(Sisson et al. 2009). Thus, it can be said that a prolonged 
period under constant artificial illumination, which is so 
typical of modern man, disrupts the physiological rhythm 
of work of the epiphysis and, possibly, acts as an additio­
nal factor that, together with overeating and low physical 
activity, leads to arterial hypertension, dyslipidemia and 
diabetes, all this resulting in sudden cardiovascular com­
plications (Arushanyan 2012b, Arushanyan 2013a).
In this regard, of special interest for scientists now is 
melatonin, an epitope hormone, in whose spectrum of 
pharmacological activity there is an ability to improve 
microcirculation of blood in the brain, to activate cellular 
and humoral immunity, to increase stress resistance and 
to reduce chemotherapy toxicity. Melatonin involvement 
in the development of food aberrations has been proven, 
especially in a “night eating syndrome”. An invert corre­
lation has also been revealed between a urinary melato­
nin excretion level and a body mass index (Solovyov et 
al. 2011, Leroith 2012). Melatonin is synthesised mainly 
by the epiphysis (endocrine melatonin). Its concentrati­
on in blood of a healthy person throughout a day ran­
ges from 10-7-10-9 mg/ml (Arushanyan 2013b, Bibik and 
Shipilova 2015, Molchanov et al. 2011). Melatonin has 
immunomodulating, geroprotective, anticarcinogenic, 
biorhythmological, sedative, antidepressant and a general 
stimulating effect on the body (Molchanov et al. 2011, 
Arushanyan 2011a). In smaller amounts, melatonin is 
formed in diffuse neuroendocrine system cells, EC-cells 
of the gastrointestinal tract and immune cells (paracrine 
melatonin) (Rapoport et al. 2009, Grinenko et al. 2012).
Melatonin stimulates the transportation of glucose to 
the skeletal muscles via the IRS1/PI3K signalling path­
way. The same signalling pathway leads to an increase in 
insulin secretion by p-cells (Molchanov 2012, She et al. 
2009). When taking exogenous melatonin at a dose of 5 
mg/day, patients demonstrate a decrease in body weight, 
partial normalisation of concentration of glucose, choles­
terol, triglycerides and leptin in blood (Palios et al. 2012). 
The influence of melatonin on the regulation of adipose 
tissue is assumed to be made due to MT1 receptors, which 
enhance metabolic processes, but it has not yet been de­
termined whether melatonin works directly or indirectly 
(Ryazanova 2014, Arushanyan 2011b).
At present, the proportion of palm oil in the diet of 
people living on the planet is substantially increasing. Its
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use is determined first of all by its low cost and long shelf 
life. The trend towards an increase in demand for palm oil 
leads to the fact that the latter is becoming the basis for 
many kinds of mass consumption food (margarine, milk 
fat substitute, for manufacturing “cow milk”, “cream but­
ter”, cottage cheese, yogurts, ice cream and processed 
cheese) (Amelyushkina et al. 2013, Ilyina and Radyuk 
2012, Ipatova et al. 2009). Uncontrolled consumption of 
products containing palm oil should be considered as an 
etiologic factor of alimentary obesity (Yankovskaya et al. 
2016, Cui et al. 2011).
In addition to the facts mentioned above, pharmaco­
logical therapy aimed at combating obesity has reached 
its critical stage, which is caused by the limited use of 
pharmaceutical products for weight loss due to their in­
efficiency and the risk of multiple dangerous side effects 
(Mirzoev 2015, Savelyeva 2011, Tereshchuk et al. 2014).
In this regard, studies aimed at finding effective and 
safe means of pharmacocorrection of alimentary obesity, 
caused by excessive consumption of palm oil are beco­
ming more and more relevant.
In the light of the above, the objective of this study 
was to study the influence of melatonin on the dynamics 
of body weight changes in rats, which had consumed ex­
cessive amounts of palm oil for 6 weeks.
Materials and Methods
The experiment was carried out on 150 white non-pedi­
gree rats (females and males), which were divided into 3 
groups and 3 series (immature, mature and senile rats): 
50 immature rats weighing 50-70 g; 50 mature rats weig­
hing 180-240 g and 50 senile rats weighing 260-300 g. 
The first group is intact. The animals of the second group 
(control group) received refined palm oil at a dose of 30 
g/kg on a daily basis for a period of 6 weeks. The rats 
of the third group (experimental group) received melato­
nin intragastrically at a dose of 1.9 mg/kg per day for 35 
days, after a 6-week period of excessive palm oil intake. 
During the experiment, once every 7 days, the animals’ 
weight check was done, followed by assessing the dyna­
mics of weight gain in rats in different age groups.
Over that period of time, such criteria as body weight 
gain, animals’ behaviour, their appetite and external 
signs were evaluated. The qualitative criterion of obesi­
ty development in animals was body weight gain when 
consuming palm oil as a part of their daily diet. When 
identifying glucose, total cholesterol and triglycerides, 
a colorimetric enzymatic method was used, with estera­
se, cholesterol and glucose oxidase on an analyser Ac­
cent-300. The obtained results were processed statistical­
ly on an Intel Core 2 Duo 3.0 GHz personal computer 
using standard applied software packages -  Microsoft 
Windows XP Professional, Microsoft Office 2003, Mi­
crosoft Excel Stadia 6.1/prof and Statistica.
The rats were decapitated after a 5-week pharmaco- 
correction with melatonin. The experimental animals
were kept in the vivarium of State Institution of Lugansk 
People’s Republic “Lugansk State Medical University 
named after St. Luke” (with a natural light regime, at a 
temperature of 22-24 °С, relative air humidity 40-50%). 
The studies were carried out in accordance with the rules 
of good laboratory practice in preclinical studies in the 
Russian Federation (Order of the Ministry of Healthcare 
and Social Development of the Russian Federation of 23 
August 2010, No. 708н), as well as with the rules and 
International Recommendations of the European Con­
vention for the Protection of Vertebrate Animals Used for 
Experimental and other Scientific Purposes (1997).
Results and Discussion
The long-term intake of palm oil by the rats in the control 
group resulted in a dramatic increase in their body weight 
in dynamics compared to the indicators in the rats of the 
intact group of all the ontogenetic periods under study 
(Table 1). Significantly important statistical differences 
in the rats’ weights of the intact and control groups were 
established by the authors during the end period of obser­
vation. Thus, by the end of the third week of an excessive 
intake of palm oil, the body weight of immature rats ex­
ceeded that of the animals of the intact group by 48.5% 
and by the end of the sixth week it was twice as great.
Mature animals that received palm oil added to their 
daily diet gained 26.1% of weight for females and 20.1% 
for males by the end of the third week. The excess body 
weight of mature rats by the end of the sixth week rea­
ched 44.9% for females and 35.1% for males. The stu­
dy of the data on body weight gain of senile rats of both 
sexes showed an unreliable difference in the first three 
weeks of the experiment, but by the end of the sixth week, 
a weight gain of 34.1% for females and 40.4% for males 
was recorded.
Continuous intake of palm oil by the rats of the second 
group showed a tendency to a dramatic increase in body 
weight in dynamics, in comparison with the indices of the 
rats of the intact group for all the periods of ontogenesis 
under study (Figs. 1-5).
Thus, by the end of the third week of consuming ex­
cessive amounts of palm oil, the body weight of imma­
ture rats exceeded that of the animals of the intact group 
by 48.5% and, by the end of the sixth week, it was twice 
as great.
An analysis of the body weight gain rate of immatu­
re rats showed a linear trend dependence over the period 
of observing the animals. For the animals of the control 
group, this dependence had the form: f(x) = 14.28*(N-1)+- 
Mo, (1) where N is a day of observation (from 1 to 7) and 
Mo is the initial mass at the beginning of the observation.
For the animals that received an excessive amount of 
palm oil in their diet, the only difference in the dependen­
ce was the value of the coefficient and this dependence 
can be represented as: f(x) = 35*(N-1)+Mo, (2), where N 
and Mo are the same as in formula (1) above.
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Table 1. Dynamics of Body Weight Gain in Male and Female Rats of Various Age Groups, Consuming Palm Oil in Excess (M ± 
m, n = 6-12).
Experiment time (weeks)
Group 1 2 3 4 5 6
Immature rats intact group 63.33±2.10
79.16
±2.71
97.50
±1.70
141.16
±2.00
127.50
±2.50
137.01
±1.70
Immature rats control group (palm oil) 87.50±2.14
117.50
±2.14
144.16±
3.51*
161.66
±4.40
216.66
±3.07*
267.50
±3.59*
Mature females, intact group 191.66±3.33
194.16
±2.38
197.50±
3.09
201.66
±3.07
206.66
±2.47
213.33
±1.66
Mature females, control group 208.33±5.86
228.33
±6.66
249.16±
5.83*
271.66
±66.6*
291.68
±4.94*
309.16
±3.27*
Mature males, intact group 235.00±3.65
240.83
±4.16
245.0
±4.65
246.66
±3.80
251.66
±3.80
259.16
±3.27
Mature males, control group 249.16±4.16
271.66
±6.14
294.16
±5.54
315.83
±4.90*
333.33
±5.42*
350.00
±7.30*
Senile male rats, 
intact group
293.33
±4.21
297.50
±3.81
303.33
±3.33
310.00
±3.16
314.00
±3.00
321.66
±2.78
Senile male rats, control group 311.66±6.41
335.83
±8.20
361.66
±8.53*
387.50
±6.80*
409.16
±6.63*
451.66
±7.03*
Senile female rats, intact group 280.00±3.41
284.16
±3.96
285.00
±3.87
289.16
±4.16
290.83
±4.36
292.50
±3.59
Senile female rats, control group 289.16±8.36
311.66
±9.71
336.66
±6.14
365.00
±5.62*
376.66
±6.66*
390.00
±8.56*
Note: * - P (<0.001) compared to intact group
Figure 1. Dynamics of body weight gain in immature rats, con­
suming palm oil.
■ Intact ■ Contra!
First day First week Second week Third week Fourth week Fifth week Sixth week
Figure 2. Dynamics of body weight gain in mature female rats, 
consuming palm oil.
First day First week Second week Third week Fourth week Fifth week Sixth week
Figure 3. Dynamics of body weight gain in mature male rats, 
consuming palm oil.
■ Intact ■ Control
First day First week Third week Fouth week Fifth week Sixth week
Figure 4. Dynamics of body weight gain in senile female rats, 
consuming palm oil.
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Both functions are of relative nature and can be spe­
cified by dividing the observation period into separate 
segments, but they fully reflect the tendencies of body 
weight gain. No significant differences between the expe­
rimental data and the data described in the above formu­
lae are observed (1, 2).
Mature animals that consumed palm oil added to their 
daily diet had an increase in weight by the end of the third 
week -  26.1% for females and 20.1% for males. Excess 
body weight of mature rats by the end of the sixth week 
was 44.9% for females and 35.1% for males.
The study of the data on the body weight gain of se­
nile rats of both sexes showed an unreliable difference in 
the first three weeks of the experiment, but by the end of 
the sixth week, a weight gain of 34.1% for females and 
40.4% for males was recorded.
As can be seen from the above, the data obtained in the 
series of experiments prove that excessive consumption 
of palm oil at a dose of 30 g/kg for 6 weeks leads to the 
second- and third-degree alimentary obesity in animals of 
all periods of ontogeny under study. The maximum incre­
ase in body weight (2 times) was observed in the group of 
immature animals. The pathological process that occurs 
under the above conditions can serve as an experimental 
model for alimentary obesity in white rats.
The results of the studies performed in terms of phar- 
macocorrection of alimentary obesity by means of me­
latonin have shown that the immature animals showed a 
gradual uniform loss of body weight for 5 weeks (Fig. 6). 
Conspicuous is the fact that the discontinuation of palm 
oil consumption in the control animals group does not re­
sult in body weight loss.
Mature animals that received melatonin as a pharma- 
cocorrector also gradually lost weight and, by the end of 
the 5th week, their weight was at the level of the rats from 
the intact group (Fig. 7).
In the experimental group of senile rats of both sexes, 
a decrease was found in body weight in comparison with 
that in the animals of the control group (Fig. 8) which, by 
the end of the experiment, was comparable to the indices 
in the intact group.
Continuous consumption of palm oil by the rats of 
the control group indicated a tendency for a dramatical­
ly increased concentration of glucose in blood, compa­
red to the indices of the rats from the intact group for all 
the periods of ontogenesis under study (Table 2). Thus, 
by the end of the experiment, the level of glucose in 
the blood of immature rats exceeded that of the animals 
in the intact group by 55.53%. In the group of mature 
animals, this difference was 61.62% and for senile rats 
-  41.01%.
Comparing the values of total cholesterol in the bio­
chemical analysis of blood of the immature animals from 
the control group with the similar indices of the intact 
group rats under the conditions of this experiment, an in­
crease of 1.82 times was found. For mature animals con­
suming palm oil in excess, total cholesterol values also 
increase 1.72 times and for senile rats -  1.61 times.
■ Control ■ Intact
First day First week Second week Third week Fouth week Fifth week Sixth week
Figure 5. Dynamics of body weight gain in senile male rats, 
consuming palm oil.
Figure 6. Dynamics of body weight gain in immature rats, in 
connection with pharmacocorrection by melatonin.
Figure 7. Dynamics of body weight gain in mature rats, in con­
nection with pharmacocorrection by melatonin.
Figure 8. Dynamics of body weight gain in senile male rats, in 
connection with pharmacocorrection by melatoninog/8.
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Table 2. Dynamics of Changes in Rats’ Biochemical Parameters after Excessive Consumption of Palm Oil and Pharmacocorrection 
by Melatonin (M±m, n=6-12).
Animal group
Glucose,
mmol/L
Total cholesterol, 
mmol/L Triglycerides, mmol/L
Immature 4.43±0.15 1.47±0.10 0.19±0.08
Mature 4.56±0.16 1.61±0.05 0.18±0.15
l-H
Senile rats 4.95±0.19 1.77±0.17 0.18±0.11
g Immature 6.89±0.20* 2.68±0.09* 0.67±0.34*
c Mature 7.37±0.24* 2.78±0.18* 0.76±0.45*
и Senile rats 6.98±0.22* 2.85±0.12* 0.77±0.40*
i•r ^ Immature 4.97±0.27 1.97±0.06 0.29±0.02fe eft g Mature 5.15±0.13 2.07±0.10 0.36±0.15
w Senile rats 5.56±0.21 2.12±0.08 0.38±0.21
Note: * - P (<0.001) compared to control group.
As it can be seen from Table 2, the triglycerides con­
centration in blood of the immature animals of the con­
trol group is characterised by a dramatic (3.53 times) 
increase in comparison with the indices recorded in the 
intact animals. The mature rats which consumed an ex­
cessive amount of palm oil in this experimental study 
had a triglyceride level exceeding the normal values by 
a factor of 4.22. Similar differences were found in the 
group of senile rats.
In the immature animals that received melatonin as a 
pharmacocorrector for 5 weeks, the level of glucose in 
blood slightly exceeds the values recorded in the intact 
group rats. However, it is lower by 27.87% than the indi­
ces in the group of rats that were on a high-fat diet consu­
ming palm oil. The mature animals that were given mela­
tonin as a pharmacocorrector for alimentary obesity were 
characterised by a reduced blood glucose level, 30.13% 
lower than the indicators in the control group. The blood 
glucose concentration in the senile rats that received me­
latonin after a long consumption of palm oil decreased by 
20.35% compared to those in the control group. However, 
over a 35-day period of pharmacocorrection, they did not 
reach the values of the intact group animals.
The values of total cholesterol in the blood of the im­
mature rats of the experimental group were 73.51% of 
those recorded in the rats of the control group. The matu­
re animals that received melatonin as a pharmacocorrec- 
tor were also characterised by a reduced concentration of 
total cholesterol in their blood compared to those in the 
control group. In the experimental group of senile rats of 
both sexes, no fully stabilised level of total cholesterol 
in blood was detected, but rather a steady tendency to its 
decrease in comparison with the control values.
The concentration of triglycerides in the blood of the 
immature animals of the experimental group is characte­
rised by stabilisation, although it does not reach the va­
lues recorded in the intact animals. In this experimental 
study, the mature rats that received an excessive amount 
of palm oil in their diet and melatonin as a pharmacocor- 
rector had a triglyceride level that exceeded the normal
values by a factor of two. Similar changes were detected 
in the group of senile rats.
Introduction of 30 g/kg of palm oil into a diet for 6 
weeks leads to a 1.6-1.8-times increase in the concen­
tration of total cholesterol in the biochemical analysis of 
blood of animals of different age groups compared to si­
milar indices for the intact group rats. The concentration 
of triglycerides in the blood of animals which received 
palm oil in excess is characterised by a dramatic (3.5 to 
4.2 times) increase in comparison with the rates recorded 
in the intact animals. The use of melatonin at a dose of 
1.9 mg/kg per day as a pharmacocorrector of alimentary 
obesity leads to a significant levelling of changes in the 
biochemical indices of rats of different periods of onto­
genesis.
Conclusions
The results of the studies performed in terms of pharma- 
cocorrection of alimentary obesity by means of melato­
nin identified that the immature animals showed a gradual 
uniform loss of body weight for 5 weeks. Conspicuous is 
the fact that the discontinuation of palm oil consumpti­
on in the control animals group does not result in body 
weight loss.
Introduction of 30 g/kg of palm oil into a diet for 6 
weeks leads to a 1.6-1.8-times increase in the concen­
tration of total cholesterol in the biochemical analysis 
of blood of animals of different age groups compared to 
similar indices for the intact group rats The concentra­
tion of triglycerides in the blood of animals which re­
ceived palm oil in excess is characterised by a dramatic 
(3.5 to 4.2 times) increase in comparison with the rates 
recorded in the intact animals. The use of melatonin at 
a dose of 1.9 mg/kg a day as a pharmacocorrector of 
alimentary obesity leads to a significant levelling of 
changes in the biochemical indices of rats of different 
periods of ontogenesis.
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